94 related articles for article (PubMed ID: 17701468)
1. Polyanion induced fibril growth enables the development of a reproducible assay in solution for the screening of fibril interfering compounds, and the investigation of the prion nucleation site.
Boshuizen RS; Morbin M; Mazzoleni G; Tagliavini F; Meloen RH; Langedijk JP
Amyloid; 2007 Sep; 14(3):205-19. PubMed ID: 17701468
[TBL] [Abstract][Full Text] [Related]
2. An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds.
Boshuizen RS; Langeveld JP; Salmona M; Williams A; Meloen RH; Langedijk JP
Anal Biochem; 2004 Oct; 333(2):372-80. PubMed ID: 15450815
[TBL] [Abstract][Full Text] [Related]
3. Core structure of amyloid fibrils formed by residues 106-126 of the human prion protein.
Walsh P; Simonetti K; Sharpe S
Structure; 2009 Mar; 17(3):417-26. PubMed ID: 19278656
[TBL] [Abstract][Full Text] [Related]
4. Influence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185-208.
Klajnert B; Cortijo-Arellano M; Cladera J; Majoral JP; Caminade AM; Bryszewska M
Biochem Biophys Res Commun; 2007 Dec; 364(1):20-5. PubMed ID: 17927954
[TBL] [Abstract][Full Text] [Related]
5. In vitro conversion of mammalian prion protein into amyloid fibrils displays unusual features.
Baskakov IV; Bocharova OV
Biochemistry; 2005 Feb; 44(7):2339-48. PubMed ID: 15709746
[TBL] [Abstract][Full Text] [Related]
6. Influence of dendrimer's structure on its activity against amyloid fibril formation.
Klajnert B; Cortijo-Arellano M; Cladera J; Bryszewska M
Biochem Biophys Res Commun; 2006 Jun; 345(1):21-8. PubMed ID: 16674918
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions.
Porat Y; Mazor Y; Efrat S; Gazit E
Biochemistry; 2004 Nov; 43(45):14454-62. PubMed ID: 15533050
[TBL] [Abstract][Full Text] [Related]
8. Alanine scanning mutagenesis of Abeta(1-40) amyloid fibril stability.
Williams AD; Shivaprasad S; Wetzel R
J Mol Biol; 2006 Apr; 357(4):1283-94. PubMed ID: 16476445
[TBL] [Abstract][Full Text] [Related]
9. Amyloid aggregates of the prion peptide PrP106-126 are destabilised by oxidation and by the action of dendrimers.
Heegaard PM; Pedersen HG; Flink J; Boas U
FEBS Lett; 2004 Nov; 577(1-2):127-33. PubMed ID: 15527773
[TBL] [Abstract][Full Text] [Related]
10. Steric zipper of the amyloid fibrils formed by residues 109-122 of the Syrian hamster prion protein.
Lee SW; Mou Y; Lin SY; Chou FC; Tseng WH; Chen CH; Lu CY; Yu SS; Chan JC
J Mol Biol; 2008 May; 378(5):1142-54. PubMed ID: 18423487
[TBL] [Abstract][Full Text] [Related]
11. Amyloid fibril formation by peptide LYS (11-36) in aqueous trifluoroethanol.
Liu W; Prausnitz JM; Blanch HW
Biomacromolecules; 2004; 5(5):1818-23. PubMed ID: 15360293
[TBL] [Abstract][Full Text] [Related]
12. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking.
Konno T; Morii T; Hirata A; Sato S; Oiki S; Ikura K
Biochemistry; 2005 Feb; 44(6):2072-9. PubMed ID: 15697232
[TBL] [Abstract][Full Text] [Related]
13. Divergent heparin-induced fibrillation pathways of a prion amyloidogenic determinant.
Bazar E; Jelinek R
Chembiochem; 2010 Sep; 11(14):1997-2002. PubMed ID: 20799315
[TBL] [Abstract][Full Text] [Related]
14. Effects of randomizing the Sup35NM prion domain sequence on formation of amyloid fibrils in vitro.
Liu Y; Wei H; Wang J; Qu J; Zhao W; Tao H
Biochem Biophys Res Commun; 2007 Feb; 353(1):139-46. PubMed ID: 17166483
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of a spontaneously aggregating amyloid-forming variant of human PrP((90-231)) through phage-display screening of variants randomized between residues 101 and 112.
Verma A; Sharma S; Ganguly NK; Majumdar S; Guptasarma P; Luthra-Guptasarma M
Int J Biochem Cell Biol; 2008; 40(4):663-76. PubMed ID: 18023239
[TBL] [Abstract][Full Text] [Related]
16. Acetylcholinesterase as an amyloid enhancing factor in PrP82-146 aggregation process.
Pera M; MartÃnez-Otero A; Colombo L; Salmona M; Ruiz-Molina D; Badia A; Clos MV
Mol Cell Neurosci; 2009 Feb; 40(2):217-24. PubMed ID: 19038345
[TBL] [Abstract][Full Text] [Related]
17. Tuning the conformational properties of the prion peptide.
Ho CC; Lee LY; Huang KT; Lin CC; Ku MY; Yang CC; Chan SI; Hsu RL; Chen RP
Proteins; 2009 Jul; 76(1):213-25. PubMed ID: 19137620
[TBL] [Abstract][Full Text] [Related]
18. Switch-peptides: design and characterization of controllable super-amyloid-forming host-guest peptides as tools for identifying anti-amyloid agents.
Camus MS; Dos Santos S; Chandravarkar A; Mandal B; Schmid AW; Tuchscherer G; Mutter M; Lashuel HA
Chembiochem; 2008 Sep; 9(13):2104-12. PubMed ID: 18683159
[TBL] [Abstract][Full Text] [Related]
19. Morphology and secondary structure of stable beta-oligomers formed by amyloid peptide PrP(106-126).
Walsh P; Yau J; Simonetti K; Sharpe S
Biochemistry; 2009 Jun; 48(25):5779-81. PubMed ID: 19476383
[TBL] [Abstract][Full Text] [Related]
20. Highly accelerated self-assembly and fibrillation of prion peptides on solid surfaces.
Ku SH; Park CB
Langmuir; 2008 Dec; 24(24):13822-7. PubMed ID: 19053635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
